BR112022013620A2 - Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos - Google Patents
Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmosInfo
- Publication number
- BR112022013620A2 BR112022013620A2 BR112022013620A BR112022013620A BR112022013620A2 BR 112022013620 A2 BR112022013620 A2 BR 112022013620A2 BR 112022013620 A BR112022013620 A BR 112022013620A BR 112022013620 A BR112022013620 A BR 112022013620A BR 112022013620 A2 BR112022013620 A2 BR 112022013620A2
- Authority
- BR
- Brazil
- Prior art keywords
- glycoprotein
- methods
- adenoviral vectors
- vectors encoding
- viral antigens
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title abstract 3
- 108090000288 Glycoproteins Proteins 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title abstract 2
- 231100000283 hepatitis Toxicity 0.000 title abstract 2
- 241001529453 unidentified herpesvirus Species 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 2
- 108700024845 Hepatitis B virus P Proteins 0.000 abstract 2
- 241000700584 Simplexvirus Species 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958827P | 2020-01-09 | 2020-01-09 | |
| US202062958809P | 2020-01-09 | 2020-01-09 | |
| US202062967104P | 2020-01-29 | 2020-01-29 | |
| US202062967242P | 2020-01-29 | 2020-01-29 | |
| US202063064506P | 2020-08-12 | 2020-08-12 | |
| US202063064571P | 2020-08-12 | 2020-08-12 | |
| US202063112219P | 2020-11-11 | 2020-11-11 | |
| US202063112202P | 2020-11-11 | 2020-11-11 | |
| PCT/US2021/012630 WO2021142212A1 (en) | 2020-01-09 | 2021-01-08 | Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013620A2 true BR112022013620A2 (pt) | 2022-09-13 |
Family
ID=74505354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013620A BR112022013620A2 (pt) | 2020-01-09 | 2021-01-08 | Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US12605444B2 (https=) |
| EP (1) | EP4087605A1 (https=) |
| JP (2) | JP7696909B2 (https=) |
| KR (1) | KR20220163354A (https=) |
| CN (2) | CN115335076B (https=) |
| AU (1) | AU2021205936A1 (https=) |
| BR (1) | BR112022013620A2 (https=) |
| CA (1) | CA3166989A1 (https=) |
| IL (1) | IL294387A (https=) |
| MX (1) | MX2022008572A (https=) |
| PH (1) | PH12022551648A1 (https=) |
| WO (1) | WO2021142212A1 (https=) |
| ZA (1) | ZA202310905B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL294387A (en) * | 2020-01-09 | 2022-08-01 | Virion Therapeutics Llc | Adenovirus vectors encoding hepatitis b virus antigens fused to herpesvirus glycoprotein d and methods of using them |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054262A1 (en) | 2003-03-28 | 2007-03-08 | Baker Denise M | Methods of identifying optimal variants of peptide epitopes |
| US20090246220A1 (en) * | 2006-08-28 | 2009-10-01 | Ertl Hildegund C J | Constructs for enhancing immune responses |
| EA028659B1 (ru) * | 2011-02-12 | 2017-12-29 | Глоубиммьюн, Инк. | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| EP2959915A1 (en) * | 2014-06-23 | 2015-12-30 | Institut Pasteur | A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection |
| CN105367662B (zh) * | 2014-08-29 | 2021-03-12 | 汤正好 | 一种hbv相关的融合蛋白、其制备方法及其应用 |
| US11324819B2 (en) | 2016-04-06 | 2022-05-10 | University Of Washington | Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen |
| SG11201900808SA (en) | 2016-08-01 | 2019-02-27 | Wistar Inst | Compositions and methods of replication deficient adenoviral vectors for vaccine applications |
| CN119770638A (zh) * | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| IL294387A (en) * | 2020-01-09 | 2022-08-01 | Virion Therapeutics Llc | Adenovirus vectors encoding hepatitis b virus antigens fused to herpesvirus glycoprotein d and methods of using them |
-
2021
- 2021-01-08 IL IL294387A patent/IL294387A/en unknown
- 2021-01-08 CN CN202180019813.3A patent/CN115335076B/zh active Active
- 2021-01-08 KR KR1020227027069A patent/KR20220163354A/ko active Pending
- 2021-01-08 JP JP2022542413A patent/JP7696909B2/ja active Active
- 2021-01-08 CA CA3166989A patent/CA3166989A1/en active Pending
- 2021-01-08 AU AU2021205936A patent/AU2021205936A1/en active Pending
- 2021-01-08 MX MX2022008572A patent/MX2022008572A/es unknown
- 2021-01-08 PH PH1/2022/551648A patent/PH12022551648A1/en unknown
- 2021-01-08 WO PCT/US2021/012630 patent/WO2021142212A1/en not_active Ceased
- 2021-01-08 EP EP21703111.1A patent/EP4087605A1/en active Pending
- 2021-01-08 BR BR112022013620A patent/BR112022013620A2/pt unknown
- 2021-01-08 US US17/790,259 patent/US12605444B2/en active Active
- 2021-01-08 CN CN202511456350.3A patent/CN121221754A/zh active Pending
- 2021-08-27 US US17/459,313 patent/US11291716B2/en active Active
-
2022
- 2022-02-24 US US17/679,356 patent/US11850282B2/en active Active
-
2023
- 2023-10-24 US US18/492,945 patent/US12290561B2/en active Active
- 2023-11-27 ZA ZA2023/10905A patent/ZA202310905B/en unknown
-
2025
- 2025-04-04 US US19/170,785 patent/US20250228934A1/en active Pending
- 2025-06-11 JP JP2025097871A patent/JP2025124904A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220163354A (ko) | 2022-12-09 |
| JP2025124904A (ja) | 2025-08-26 |
| US12605444B2 (en) | 2026-04-21 |
| CN121221754A (zh) | 2025-12-30 |
| CN115335076B (zh) | 2025-10-28 |
| JP7696909B2 (ja) | 2025-06-23 |
| IL294387A (en) | 2022-08-01 |
| JP2023510544A (ja) | 2023-03-14 |
| CA3166989A1 (en) | 2021-07-15 |
| US20220175913A1 (en) | 2022-06-09 |
| US11291716B2 (en) | 2022-04-05 |
| ZA202310905B (en) | 2025-06-25 |
| US11850282B2 (en) | 2023-12-26 |
| US20240091347A1 (en) | 2024-03-21 |
| US20250228934A1 (en) | 2025-07-17 |
| EP4087605A1 (en) | 2022-11-16 |
| US20230063089A1 (en) | 2023-03-02 |
| CN115335076A (zh) | 2022-11-11 |
| US12290561B2 (en) | 2025-05-06 |
| WO2021142212A1 (en) | 2021-07-15 |
| PH12022551648A1 (en) | 2024-02-12 |
| MX2022008572A (es) | 2022-09-23 |
| AU2021205936A1 (en) | 2022-07-21 |
| US20210393770A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021013878A2 (es) | Vectores de virus adenoasociado recombinantes | |
| MX2021003175A (es) | Vacuna contra el virus de la peste porcina africana. | |
| Li et al. | Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates | |
| EA202192570A1 (ru) | Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение | |
| CL2023000264A1 (es) | Nuevos vectores virales adeno-asociados dirigidos al hígado | |
| BR112022016550A2 (pt) | Proteínas de ligação a flt3 e métodos de uso | |
| AR056138A1 (es) | Procedimiento para la expresion recombinante de un polipeptido | |
| DK11789D0 (da) | Rekombinante vaccinia-vira | |
| DK0596979T3 (da) | Rekombinante nucleinsyrer fra plantevirus | |
| PE20081686A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
| CR20200170A (es) | Receptores de células t que reconocen p53 mutado | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| WO2021198706A3 (en) | Coronavirus vaccines | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| ES2061708T3 (es) | Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus. | |
| CY1105680T1 (el) | Μολυσματικος κλωνος cdna βορειοαμερικανικου ιου χοιρειου αναπαραγωγικου και αναπνευστικου συνδρομου (prrs) και χρησεις αυτου | |
| ATE325882T1 (de) | Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind | |
| BR112022011099A2 (pt) | Tratamento de doenças relacionadas ao vírus da hepatite b | |
| FI3445397T3 (fi) | Integraalisen membraaniproteiinin näyttö poxviruksen solunulkoisilla vaipallisilla virioneilla | |
| MX2022014943A (es) | Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. | |
| DE3853139D1 (de) | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. | |
| ES2072928T3 (es) | Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular. | |
| BR112022013620A2 (pt) | Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos | |
| ES2058486T3 (es) | Inmunogenos nativos y recombinantes del grupo b de eimeria tenella utiles como vacunas para las coccidiosis. | |
| ECSP17075380A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos |